Threshold Reports Early Data For Combining TH-302 With Antiangiogenic Agents

(RTTNews) - Threshold Pharmaceuticals, Inc. (THLD) announced early clinical data from two single-arm, open-label Phase 1 studies assessing TH-302, an investigational, hypoxia-targeted drug, in combination with antiangiogenic agents to treat advanced solid tumors. The new data from an investigator-sponsored trial, called Study 4001, demonstrated that combination treatment with TH-302 plus Votrient achieved a clinical benefit rate of 76%.

The updated data from a company-sponsored trial known as Study 410 in patients with renal cell carcinoma and gastrointestinal stromal tumors showed partial responses to treatment with TH-302 plus Sutent.

The combination study with TH-302 plus pazopanib was conducted in 30 patients with a variety of solid tumors for whom standard therapy or palliative measures were nonexistent or no longer effective. The clinical benefit rate was 76% with 3 patients with partial responses and 16 patients with stable disease, according to the company.

TH-302 is an investigational hypoxia-targeted drug that is designed to be activated under tumor hypoxic conditions, a hallmark of many cancers.

In addition, the preclinical data for combining TH-302 with Gemzar and Abraxane in models of pancreatic cancer would be presented at the meeting on Tuesday October 22 showing in xenograft models greater anti-tumor activity associated with the "triplet" compared with that of the doublet, and without additive hematological toxicity or peripheral neuropathy.